US 7232572 B2 - Methods Of Treating Rosacea - The Lens - Free & Open Patent and Scholarly Search

Patents

US 7232572 B2

Abstract

A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.

Claims

A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a tetracycline compound, or a pharmaceutically acceptable salt thereof, in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount that results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
A method according to claim 1, wherein said tetracycline compound is minocycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.8 μg/ml.
A method according to claim 1, wherein said tetracycline compound is tetracycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.5 μg/ml.
A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration which is 10-80% of the minimum antibiotic serum concentration.
A method according to claim 4, wherein said antibiotic tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.
A method according to claim 5, wherein said antibiotic tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.
A method according to claim 6, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
A method according to claim 6, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 20 milligrams twice daily.
A method according to claim 7, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.
A method according to claim 9, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.
A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which is 10-70% of the antibiotic amount.
A method according to claim 1, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.
A method according to claim 12, wherein said doxycycline is doxycycline monohydrate.
A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.
A method according to claim 14, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.
A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered twice a day in a dose of 20 mg.
A method according to claim 1, wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.
A method according to claim 4, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of approximately 1.0 μg/ml.
A method according to claim 4, wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.
A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a hydrate of doxycycline in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the hydrate of doxycycline is administered in an amount that results in no reduction of skin microflora during a six-month treatment, said method not comprising administering a bisphosphonate compound.
A method according to claim 20, wherein said hydrate of doxycycline is doxycycline monohydrate.
A method according to claim 20 wherein said hydrate of doxycycline is administered in an amount which is 10-70% of the antibiotic amount.
A method according to claim 20, wherein said hydrate of doxycycline is administered in an amount of 40 milligrams.
A method according to claim 20, wherein said hydrate of doxycycline is administered by sustained release.
A method according to claim 20, wherein said hydrate of doxycycline is administered twice a day in a dose of 20 mg.
A method according to claim 23, wherein said hydrate of doxycycline is administered once a day.

Owners (US)

Galderma Laboratories Inc (Jul 29 2008)
Explore more patents:
- View all patents where Owners (US) GALDERMA LABORATORIES INC
Collagenex Pharmaceuticals Inc (Jun 01 2005)
Explore more patents:
- View all patents where Owners (US) COLLAGENEX PHARMACEUTICALS INC

Applicants

Collagenex Pharm Inc
Explore more patents:
- View all patents where Applicants COLLAGENEX PHARM INC

Inventors

Ashley Robert A
Explore more patents:
- View all patents where Inventors ASHLEY ROBERT A
- View all scholarly literature where Author = ASHLEY ROBERT A

CPC Classifications

A61K31/135
Explore more patents:
- View all patents where CPC Classifications A61K31/135
- View in Classification Explorer
A61K31/65
Explore more patents:
- View all patents where CPC Classifications A61K31/65
- View in Classification Explorer
A61K9/0053
Explore more patents:
- View all patents where CPC Classifications A61K9/0053
- View in Classification Explorer
D06M16/00
Explore more patents:
- View all patents where CPC Classifications D06M16/00
- View in Classification Explorer

IPC Classifications

A01N37/18
Explore more patents:
- View all patents where IPC Classifications A01N37/18
- View in Classification Explorer
A61K31/65
Explore more patents:
- View all patents where IPC Classifications A61K31/65
- View in Classification Explorer
A61K9/20
Explore more patents:
- View all patents where IPC Classifications A61K9/20
- View in Classification Explorer
A61K9/48
Explore more patents:
- View all patents where IPC Classifications A61K9/48
- View in Classification Explorer
A61K9/68
Explore more patents:
- View all patents where IPC Classifications A61K9/68
- View in Classification Explorer

US Classifications

424/401
Explore more patents:
- View all patents where US Classifications 424/401
- View in Classification Explorer
424/440
Explore more patents:
- View all patents where US Classifications 424/440
- View in Classification Explorer
424/451
Explore more patents:
- View all patents where US Classifications 424/451
- View in Classification Explorer
424/464
Explore more patents:
- View all patents where US Classifications 424/464
- View in Classification Explorer
514/152
Explore more patents:
- View all patents where US Classifications 514/152
- View in Classification Explorer

Download PDF

Document Preview

Document History

Publication: Jun 19, 2007
US 7232572 B2
Application: Feb 18, 2005
US 6186605 A
Priority: Feb 18, 2005
US 6186605 A
Priority: Oct 15, 2002
US 27249902 A
Priority: Apr 5, 2002
US 11770902 A
Priority: Sep 26, 2001
US 32548901 P
Priority: Apr 5, 2001
US 28191601 P